Sands Capital Life Sciences Pulse Fund II, L.P. - 30 Jun 2025 SCHEDULE 13G/A Report for Acrivon Therapeutics, Inc. Common Stock, par value $0.001 per share (ACRV)

Filing Manager
Sands Capital Life Sciences Pulse Fund II, L.P.
Reporting Manager
Sands Capital Life Sciences Pulse Fund II, L.P.
Security
Acrivon Therapeutics, Inc. Common Stock, par value $0.001 per share
Symbol
ACRV
Shares outstanding
31,214,779 shares
Disclosed Ownership
2,122,605 shares
Ownership
6.8%
Form type
SCHEDULE 13G/A
Filing time
13 Aug 2025, 11:12:23 UTC
Date of event
30 Jun 2025
SEC
View on sec.gov

Reporting Managers (3)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Sands Capital Life Sciences Pulse Fund II, L.P. 6.8% 2,122,605 0 2,122,605 /s/ Jonathan Goodman Jonathan Goodman, General Counsel of the GP of the GP of Sands Capital Life Sciences Pulse Fund II, L.P.
Sands Capital Alternatives, LLC 6.8% 2,122,605 0 2,122,605 /s/ Jonathan Goodman Jonathan Goodman, General Counsel
SANDS FRANK M. 6.8% 2,122,605 0 2,122,605 /s/ Frank M. Sands Frank M. Sands